Free Trial

Rigel Pharmaceuticals (RIGL) Competitors

Rigel Pharmaceuticals logo
$20.13 +2.78 (+16.02%)
As of 01/17/2025 04:00 PM Eastern

RIGL vs. INVA, OPK, IRWD, EBS, CDXS, XOMA, VNDA, VSTM, SGMO, and LXRX

Should you be buying Rigel Pharmaceuticals stock or one of its competitors? The main competitors of Rigel Pharmaceuticals include Innoviva (INVA), OPKO Health (OPK), Ironwood Pharmaceuticals (IRWD), Emergent BioSolutions (EBS), Codexis (CDXS), XOMA (XOMA), Vanda Pharmaceuticals (VNDA), Verastem (VSTM), Sangamo Therapeutics (SGMO), and Lexicon Pharmaceuticals (LXRX). These companies are all part of the "biotechnology" industry.

Rigel Pharmaceuticals vs.

Rigel Pharmaceuticals (NASDAQ:RIGL) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, community ranking, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

Innoviva has a net margin of 18.31% compared to Rigel Pharmaceuticals' net margin of 2.46%. Innoviva's return on equity of 20.84% beat Rigel Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Rigel Pharmaceuticals2.46% -14.80% 3.03%
Innoviva 18.31%20.84%11.38%

Rigel Pharmaceuticals received 162 more outperform votes than Innoviva when rated by MarketBeat users. Likewise, 68.85% of users gave Rigel Pharmaceuticals an outperform vote while only 57.58% of users gave Innoviva an outperform vote.

CompanyUnderperformOutperform
Rigel PharmaceuticalsOutperform Votes
462
68.85%
Underperform Votes
209
31.15%
InnovivaOutperform Votes
300
57.58%
Underperform Votes
221
42.42%

66.2% of Rigel Pharmaceuticals shares are held by institutional investors. Comparatively, 99.1% of Innoviva shares are held by institutional investors. 9.0% of Rigel Pharmaceuticals shares are held by company insiders. Comparatively, 1.7% of Innoviva shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Innoviva has higher revenue and earnings than Rigel Pharmaceuticals. Innoviva is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rigel Pharmaceuticals$116.88M3.03-$25.09M$0.14143.80
Innoviva$310.46M3.75$179.72M$0.6926.93

In the previous week, Rigel Pharmaceuticals had 19 more articles in the media than Innoviva. MarketBeat recorded 20 mentions for Rigel Pharmaceuticals and 1 mentions for Innoviva. Innoviva's average media sentiment score of 1.78 beat Rigel Pharmaceuticals' score of 0.58 indicating that Innoviva is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rigel Pharmaceuticals
3 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Innoviva
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Rigel Pharmaceuticals currently has a consensus price target of $36.20, suggesting a potential upside of 79.83%. Given Rigel Pharmaceuticals' higher probable upside, equities research analysts clearly believe Rigel Pharmaceuticals is more favorable than Innoviva.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rigel Pharmaceuticals
0 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.40
Innoviva
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Rigel Pharmaceuticals has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500. Comparatively, Innoviva has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500.

Summary

Innoviva beats Rigel Pharmaceuticals on 10 of the 18 factors compared between the two stocks.

Get Rigel Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RIGL vs. The Competition

MetricRigel PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$286.24M$6.37B$5.23B$8.96B
Dividend YieldN/A2.94%5.13%4.04%
P/E Ratio143.808.3083.3616.84
Price / Sales3.03311.691,257.9179.09
Price / CashN/A61.4443.8235.97
Price / Book-12.276.055.324.79
Net Income-$25.09M$154.90M$122.78M$224.99M
7 Day Performance23.88%-1.73%-0.20%1.50%
1 Month Performance17.93%2.68%3.71%4.68%
1 Year Performance50.22%2.76%27.30%20.92%

Rigel Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RIGL
Rigel Pharmaceuticals
3.9495 of 5 stars
$20.13
+16.0%
$36.20
+79.8%
+49.1%$286.24M$116.88M143.80160Analyst Forecast
Short Interest ↑
Analyst Revision
News Coverage
Gap Up
High Trading Volume
INVA
Innoviva
1.6411 of 5 stars
$17.50
+1.3%
N/A+15.4%$1.10B$352.75M25.36100Positive News
OPK
OPKO Health
4.462 of 5 stars
$1.53
+4.1%
$2.75
+79.7%
+49.1%$1.04B$863.50M-8.053,930Analyst Downgrade
Insider Trade
News Coverage
IRWD
Ironwood Pharmaceuticals
4.3573 of 5 stars
$3.60
-9.1%
$10.40
+188.9%
-70.4%$576.10M$378.42M-120.00220Short Interest ↓
News Coverage
Positive News
Gap Down
EBS
Emergent BioSolutions
4.2377 of 5 stars
$9.36
-5.3%
$14.33
+53.1%
+415.9%$507.16M$1.09B-2.281,600Analyst Upgrade
Gap Down
CDXS
Codexis
3.8752 of 5 stars
$4.50
+2.5%
$8.33
+85.2%
+86.6%$366.20M$64.45M-5.17250Short Interest ↑
News Coverage
XOMA
XOMA
4.1696 of 5 stars
$25.52
+1.4%
$81.50
+219.4%
+38.4%$300.70M$9.71M-7.3310Analyst Upgrade
VNDA
Vanda Pharmaceuticals
3.8895 of 5 stars
$4.50
-2.2%
$15.50
+244.4%
+16.0%$262.39M$190.86M-16.07290
VSTM
Verastem
2.7566 of 5 stars
$5.33
-7.0%
$13.38
+150.9%
-52.0%$237.22M$10M-1.6750
SGMO
Sangamo Therapeutics
2.7783 of 5 stars
$1.06
-9.0%
$5.50
+418.9%
+145.2%$221.17M$52.29M-1.41480Gap Down
LXRX
Lexicon Pharmaceuticals
1.746 of 5 stars
$0.68
-11.7%
$6.00
+787.2%
-49.6%$166.53M$5.23M-0.90140

Related Companies and Tools


This page (NASDAQ:RIGL) was last updated on 1/18/2025 by MarketBeat.com Staff
From Our Partners